Drug intelligence / Profile preview

BG44

Development stage: Preclinical
Lead developer: Beijing Biostar Pharmaceuticals
Modality: Small Molecules

Overview

BG44 is a chemical drug developed by Beijing Biostar Pharmaceuticals Co. Ltd. It is primarily focused on treating solid tumors and is currently in the preclinical phase. The exact mechanism of action is not specified in the available data.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on BG44.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG44.

Explore the full profile